secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2024-10-25T23:59:59+00:00
Accession:  0001193125-24-243475
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences reports interim TYRA-300 data: 54.5% confirmed PR in FGFR3+ mUC at ≥90 mg QD
--------------------------------------------------------------------------------

- As of Aug 15, 2024, 41 patients enrolled in SURF301 Phase 1; 6/11 (54.5%) FGFR3+ mUC patients at ≥90 mg QD achieved confirmed partial response, 3 ongoing.
- 100% disease control rate (PR + stable disease) observed in patients at ≥90 mg QD.
- TYRA-300 generally well-tolerated; no Gr4+ TRAEs, 1 DLT (Gr3 diarrhea) and 1 discontinuation (Gr3 ALT) at 90 mg QD.
- Director Siddarth Subramony resigned from Board and Compensation Committee effective Oct 24, 2024, not due to any disagreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312524243475/0001193125-24-243475-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312524243475/d898462d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-243475

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer